Abstract: The present disclosure provides pharmaceutical compositions that include one or more selective estrogen receptor modulator(s) (SERM(s), e.g., Lasofoxifene) and four or more pharmaceutically acceptable excipients. The pharmaceutical compositions may be able to form nanodroplets (e.g., by self-nanoemulsifying) in vaginal fluid and to deliver the one or more SERM(s) to the vagina of a female subject. The pharmaceutical compositions may be useful in treating or preventing vulvovaginal atrophy, dyspareunia, sexual dysfunction, osteoporosis, or breast cancer in a female subject.